EGRX — Eagle Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $12.99m
- $67.83m
- $316.61m
Eagle Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Eagle Pharmaceuticals Reports Third Quarter 2021 Results
Eagle Pharmaceuticals Inc expected to post earnings of 83 cents a share - Earnings Preview
Eagle Pharmaceuticals Inc expected to post earnings of 83 cents a share - Earnings Preview
Brief: Eagle Pharmaceuticals Appoints Scott Tarriff As President, Effective Immediately
Analysts see big hit to Endo after patent ruling in favor of Eagle Pharma
U.S. RESEARCH ROUNDUP-American Water Works Company, Endo International, Talis Biomedical
Brief: Endo Comments On Non-Infringement Ruling In VASOSTRICT Patent Litigation
Brief: Eagle Pharmaceuticals Wins Vasopressin Patent Trial
Brief: Eagle Pharmaceuticals Granted Additional Patent For Bendamustine Franchise
Brief: Eagle Pharmaceuticals Announces Licensing Agreement With Combioxin SA
U.S. RESEARCH ROUNDUP-Bluebird Bio, Smiledirectclub, Whitehorse Finance
Eagle Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Eagle Pharmaceuticals Reports Second Quarter 2021 Results
Brief: Eagle Pharmaceuticals Announces Licensing Agreement With Aop Orphan For U.S. Commercial Rights To Landiolol, A Beta-1 Adrenergic Blocker
Eagle Pharmaceuticals Inc expected to post earnings of 80 cents a share - Earnings Preview
Brief: Eagle Pharmaceuticals Announces FDA Maintains Prioritization Of ANDA For Vasopressin
Brief: Eagle Pharmaceuticals Submits Response To Complete Response Letter From FDA For Vasopressin
Eagle Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary